[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Acumen Pharmaceuticals Inc (ABOS)

Acumen Pharmaceuticals Inc (ABOS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 164,680
  • Shares Outstanding, K 72,228
  • Annual Sales, $ 0 K
  • Annual Income, $ -121,340 K
  • EBIT $ -124 M
  • EBITDA $ -124 M
  • 60-Month Beta 0.32
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.97

Options Overview Details

View History
  • Implied Volatility 63.64% (-44.08%)
  • Historical Volatility 52.50%
  • IV Percentile 3%
  • IV Rank 0.00%
  • IV High 790.23% on 08/13/25
  • IV Low 63.64% on 05/18/26
  • Expected Move (DTE 31) 0.88 (41.31%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 8
  • Volume Avg (30-Day) 96
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 1,043
  • Open Int (30-Day) 2,001
  • Expected Range 1.26 to 3.02

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.36
  • Number of Estimates 1
  • High Estimate $-0.36
  • Low Estimate $-0.36
  • Prior Year $-0.68
  • Growth Rate Est. (year over year) +47.06%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.14 +0.55%
on 05/18/26
2.99 -28.04%
on 04/20/26
-0.67 (-23.70%)
since 04/17/26
3-Month
2.14 +0.55%
on 05/18/26
3.60 -40.23%
on 03/16/26
-0.46 (-17.56%)
since 02/18/26
52-Week
0.99 +117.34%
on 05/28/25
3.60 -40.23%
on 03/16/26
+1.08 (+101.09%)
since 05/16/25

Most Recent Stories

More News
Acumen Pharmaceuticals Q1 Earnings Call Highlights

Acumen Pharmaceuticals (NASDAQ:ABOS) said its Phase 2 ALTITUDE-AD trial of sabirnetug remains on track, with top-line results expected late in 2026, as the company continues to advance its broader Alzheimer’s...

ABOS : 2.14 (-6.14%)
Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights

Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026 Lead clinical candidate IND filing in...

ABOS : 2.14 (-6.14%)
Acumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care Conference

NEWTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid...

ABOS : 2.14 (-6.14%)
Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026

NEWTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics...

ABOS : 2.14 (-6.14%)
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights

Expect to report topline results for ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in late 2026 Lead clinical candidate IND filing in...

ABOS : 2.14 (-6.14%)
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026

NEWTON, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics...

ABOS : 2.14 (-6.14%)
Acumen Pharmaceuticals Presents Studies on Enhanced Brain Delivery™, Biomarker Research, and Novel Antibodies at Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026

NEWTON, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta...

ABOS : 2.14 (-6.14%)
Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio

Financing demonstrates conviction in oligomer-selective approach and follows strong preclinical data, including in vitro , in vivo and non-human primate study results, that support development candidates...

ABOS : 2.14 (-6.14%)
Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum

NEWTON, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid...

ABOS : 2.14 (-6.14%)
Acumen Pharmaceuticals to Showcase Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026

NEWTON, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid...

ABOS : 2.14 (-6.14%)

Business Summary

Acumen Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It involved in developing a novel disease for Alzheimer. The company's product pipeline consist ACU193. Acumen Pharmaceuticals Inc. is based in CHARLOTTESVILLE, Va.

See More

Key Turning Points

3rd Resistance Point 2.51
2nd Resistance Point 2.45
1st Resistance Point 2.37
Last Price 2.14
1st Support Level 2.23
2nd Support Level 2.17
3rd Support Level 2.09

See More

52-Week High 3.60
Fibonacci 61.8% 2.60
Fibonacci 50% 2.30
Last Price 2.14
Fibonacci 38.2% 1.99
52-Week Low 0.99

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.